- Home
- MRSN vs BLUE Comparison
MRSN vs BLUE Comparison
Compare MRSN & BLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- BLUE
- Stock Information
- Founded
- MRSN 2001
- BLUE 1992
- Country
- MRSN United States
- BLUE United States
- Employees
- MRSN N/A
- BLUE N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- BLUE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MRSN Health Care
- BLUE Health Care
- Exchange
- MRSN Nasdaq
- BLUE Nasdaq
- Market Cap
- MRSN 40.7M
- BLUE 36.9M
- IPO Year
- MRSN 2017
- BLUE 2013
- Fundamental
- Price
- MRSN $0.37
- BLUE $4.97
- Analyst Decision
- MRSN Strong Buy
- BLUE Hold
- Analyst Count
- MRSN 5
- BLUE 7
- Target Price
- MRSN $5.75
- BLUE $44.60
- AVG Volume (30 Days)
- MRSN 3.1M
- BLUE 1.1M
- Earning Date
- MRSN 05-15-2025
- BLUE 05-14-2025
- Dividend Yield
- MRSN N/A
- BLUE N/A
- EPS Growth
- MRSN N/A
- BLUE N/A
- EPS
- MRSN N/A
- BLUE N/A
- Revenue
- MRSN $34,006,000.00
- BLUE $103,946,000.00
- Revenue This Year
- MRSN N/A
- BLUE $205.45
- Revenue Next Year
- MRSN N/A
- BLUE $3.74
- P/E Ratio
- MRSN N/A
- BLUE N/A
- Revenue Growth
- MRSN N/A
- BLUE 127.51
- 52 Week Low
- MRSN $0.26
- BLUE $3.20
- 52 Week High
- MRSN $2.83
- BLUE $28.60
- Technical
- Relative Strength Index (RSI)
- MRSN 51.71
- BLUE 62.82
- Support Level
- MRSN $0.33
- BLUE $4.40
- Resistance Level
- MRSN $0.38
- BLUE $5.01
- Average True Range (ATR)
- MRSN 0.04
- BLUE 0.11
- MACD
- MRSN 0.00
- BLUE 0.06
- Stochastic Oscillator
- MRSN 58.60
- BLUE 96.72
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
About BLUE bluebird bio Inc.
bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.